Cronos Group Inc. (CRON) shares advanced to a 52-week high of $3.44 on Monday, the strongest level since August 2025, after the cannabis company reported second-quarter results that exceeded analyst expectations.
The Toronto-based firm closed at $3.41 on Aug. 24, up 3.02% on the day, while after-hours trading showed an additional gain of 2.35% to $3.49 at 13:16 UTC. Year-to-date, CRON has gained 25.86%, while its trailing 12-month return stands at 31.08%.
Cronos reported Q2 revenue of $53 million, surpassing the $44.73 million consensus estimate compiled by InvestingPro. Adjusted earnings per share came in at $0.09, well above the $0.01 forecast. Gross profit reached a record $28.5 million, while adjusted EBITDA rose to $13.1 million. Operating cash flow for the quarter totaled $24 million, and the company held $827 million in cash, equivalents and investments as of June 30.
During the quarter, Cronos repurchased $60 million of its own shares, reducing outstanding equity while signaling confidence in its financial position. The company operates cannabis markets in Canada, Israel and select international jurisdictions.
Despite the strong performance, InvestingPro’s analysis indicated that CRON remained overvalued relative to its estimated fair value, though the stock was trading near its 52-week peak. The analysis platform also provided 12 exclusive valuation and financial health insights for subscribers.
